- Details
- Zachary Klaassen discusses the future of bladder cancer treatment with Mark Tyson. They explore the challenges of sequencing treatments for non-muscle invasive bladder cancer, particularly in BCG-naive and unresponsive patients. Dr. Tyson emphasizes the evolving landscape with multiple emerging drugs like Adstiladrin and N-803, which recently received FDA approval. They examine the difficulty in d...
|
- Details
- Sam Chang engages with Ashish Kamat to discuss integrating Adstiladrin into regular clinical practice. During their conversation, Dr. Kamat elaborates on Adstiladrin's journey from clinical trials to its current commercial use, highlighting its 53% complete response rate. They explore the challenges and decisions involved in choosing treatments for BCG-unresponsive non-muscle invasive bladder canc...
|
- Details
- Sam Chang speaks with Mark Tyson about the BOND-003 trial's findings on cretostimogene grenadenorepvec for treating BCG unresponsive carcinoma in situ of the bladder. Dr. Tyson explains the dual-action mechanism of the drug, combining direct tumor cell destruction with enhanced immune response activation. Impressively, the trial shows a 75.2% complete response rate at various time points with a ti...
|
- Details
- Ashish Kamat introduces Stephen B. Williams who discusses findings from his study on blue light cystoscopy in bladder cancer treatment, conducted within the VA healthcare system. The study utilized a propensity score-matched analysis to compare the outcomes of blue light versus white light cystoscopy, focusing on bladder cancer recurrence, progression, and overall survival. The analysis revealed s...
|
- Details
- Ashish Kamat hosts Sam Chang to discuss the SunRISe-3 trial. Dr. Chang presents the ongoing trial investigating the efficacy of TAR-200, either alone or combined with cetrelimab, against BCG in treating patients with BCG-naive bladder cancer. TAR-200, a targeted release system using gemcitabine, is tested for its potential benefits over traditional treatments due to its unique delivery system aime...
|
- Details
- Mark Tyson presents results from the BOND-003 study, evaluating the efficacy of cretostimogene grenadenorepvec monotherapy in treating BCG-unresponsive non-muscle-invasive bladder cancer. Cretostimogene, an oncolytic adenovirus, selectively targets and destroys cancer cells while sparing normal tissue and boosting antitumor immunity. The phase III study reported a 75.2% complete response rate, wit...
|
- Details
- Ashish Kamat welcomes Siamak (Sia) Daneshmand to discuss the nuances of blue light cystoscopy and its effectiveness across different racial groups. Dr. Daneshmand discusses his team’s research into racial differences in tumor detection rates using blue light cystoscopy. He highlights the study's analysis of detection sensitivity across different races, revealing that while blue light enhances tumo...
|
- Details
- Ashish Kamat introduces Jeffrey Holzbeierlein, who discusses the recent updates to the American Urological Association's (AUA) guidelines for managing non-muscle invasive bladder cancer. Published in partnership with the Society for Urologic Oncology, these evidence-based guidelines highlight key changes from the 2016 and 2017 versions. The updates include the management of variant histologies, re...
|
- Details
- Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November 2023....
|
- Details
- Ruchika Talwar hosts Marshall Strother for a discussion on the recovery timeline following TURBT for bladder cancer. Utilizing ecological momentary assessment, Dr. Strother's study tracks patient symptoms and recovery in real-time through daily text-based surveys, offering a detailed view of the recovery process. Findings reveal most patients experience mild symptoms post-surgery, with a significa...
|
